Catalog No.
Product Name
Application
Product Information
Citations
-
Galectin-8N Inhibitor
Galectin-8-IN-2 is a selective inhibitor of galectin-8N, a member of the galectin family implicated in various biological processes. This compound exhibits significant inhibitory activity, making it a valuable tool for investigating galectin-mediated pathways and their roles in disease mechanisms. It is particularly useful for research focused on cancer, inflammation, and immune response modulation. -
Galectin-8N Activator
Galectin-8-IN-1 is a selective ligand targeting the N-terminal domain of galectin-8 (galectin-8N), exhibiting a dissociation constant (Kd) of 48 μM. This compound demonstrates a 15-fold selectivity over galectin-3, as well as significantly enhanced selectivity against other mammalian galectins. Galectin-8-IN-1 is valuable for research applications focused on galectin biology, immune responses, and cell signaling pathways. -
Galectin 4 Inhibitor
Galectin-4-IN-2 is a potent inhibitor of galectin-4C, exhibiting a dissociation constant of 1.6 mM. This compound is valuable for studies investigating the role of galectin-4 in various biological processes, including cell adhesion, immune response, and cancer biology. Research applications include elucidating the mechanisms of galectin-mediated pathways and exploring therapeutic strategies targeting galectin proteins in disease models. -
Galectin-3 Inhibitor
Galectin-3-IN-4 is a selective carboxamide inhibitor targeting galectin-3, with an IC50 of 21 nM for human galectin-3 and 167 nM for mouse galectin-3. This compound demonstrates significant selectivity, showing much higher IC50 values of 1580 nM and 2750 nM for human galectin-1 and galectin-9, respectively. Galectin-3-IN-4 is orally bioavailable, making it a valuable tool for research into the role of galectin-3 in various biological processes, including cancer, inflammation, and fibrosis. -
Gal-3 Inhibitor
Galectin-3-IN-2 is a potent multivalent inhibitor of galectin-3 (Gal-3), exhibiting an IC50 value of 8.3 μM. Galectin-3 is involved in various cancer-related metabolic processes, making this compound valuable for research into cancer biology and therapeutic development. Its application as a Gal-3 inhibitor allows for the exploration of its role in tumor progression, metastasis, and immune response modulation. -
Galectin-3 Inhibitor
Galectin-3-IN-6 is a potent inhibitor of galectin-3, displaying an IC50 of 12 nM against human galectin-3 and 12.6 nM against the mutant murine galectin-3 (V160A), along with a Kd of 13 nM. This compound effectively reduces markers of liver fibrosis, including type I collagen and α-smooth muscle actin, in murine models of acute liver injury and fibrosis. Galectin-3-IN-6 serves as a valuable tool for investigating the mechanisms and potential therapies for acute liver injury and related fibrotic conditions. -
Galectin Antagonist
SNAP 398299 is a selective antagonist of the Galectin-3 (Gal3) receptor. This compound has demonstrated potential anxiolytic and antidepressant effects by partially reversing the neuropeptide galanin-induced inhibition of dorsal raphe neuronal firing as well as the galanin-induced hyperpolarizing current. Its unique mechanism makes SNAP 398299 a valuable tool for researching the roles of galectin in neurobiology and potential therapeutic interventions for mood disorders. -
Galectin Binder
Galectin-3 antagonist 2 is a compound that specifically targets galectin-3, a β-galactoside-binding lectin. This antagonist is known to inhibit the activity of galectin-3, which has been implicated in promoting the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and contributing to drug resistance in this malignancy. It is utilized in research applications focused on cancer biology, particularly in understanding the mechanisms of leukemogenesis and the development of therapeutic strategies for leukemia. -
Gal-3 Inhibitor
Galectin-3-IN-3 is a selective inhibitor of galectin-3, exhibiting potent activity with IC50 values of 11 nM for mouse galectin-3 and 84 nM for human galectin-3. This compound serves as a valuable tool for studying the role of galectin-3 in various biological processes, including tumor progression, inflammation, and fibrosis. Its oral bioavailability allows for convenient administration in preclinical models, facilitating research in therapeutic applications targeting galectin-3-related pathologies. -
Galectin-1 Inhibitor
GB1490 is a potent galectin-1 inhibitor, exhibiting a Kd value of 0.4 μM. Additionally, it shows inhibitory activity against galectin-3 with a Kd of 2.7 μM. This compound is primarily utilized in research to investigate the role of galectins in various biological processes, including cancer progression and immune response modulation. Its selectivity and potency make it a valuable tool in studies aimed at understanding galectin-related pathways. -
Galectin-8N Inhibitor
Galectin-8N-IN-2 is a selective inhibitor of Galectin-8N, exhibiting a Ki value of 74 µM. This compound is essential for investigating the role of Galectin-8N in biological processes, particularly in modulating cell adhesion, immune responses, and tumor progression. Its inhibitory action facilitates research into therapeutic strategies targeting galectins in cancer and autoimmune diseases. -
Anti-Inflammatory Agent
Methylprednisolone aceponate is a glucocorticoid with a specific mechanism of action as a selective glucocorticoid receptor ligand, primarily functioning as an anti-inflammatory agent. It exhibits weak systemic effects, making it particularly useful in the treatment of localized inflammatory conditions. This compound is valuable for research applications targeting eczema and other inflammatory skin disorders, aiding in the understanding of their pathophysiology and potential treatments. -
Anti-inflammatory Agent
Isoflupredone acetate is a corticosteroid with potent anti-inflammatory properties. It modulates inflammatory responses and is utilized in research related to ketosis, musculoskeletal disorders, hypersensitivity, and various inflammatory diseases in animals such as cows, horses, and pigs. This compound serves as a valuable tool for studying the mechanisms of inflammation and therapeutic interventions in veterinary medicine. -
Anti-inflammatory Agent
Mazipredone free base is a glucocorticoid derivative that functions primarily as an anti-inflammatory and anti-allergic agent. It exhibits significant biological activity in reducing inflammation and managing allergic responses. This compound is particularly useful in research applications focused on inflammation-related conditions and therapeutic interventions targeting the immune response. Mazipredone free base is sensitive to oxidation and is affected by both acidic and basic environments. -
Anti-inflammatory agent
Fluocortolone is an orally active anti-inflammatory agent targeting the modulation of inflammatory responses. It is known to effectively reduce plasma fibrinogen levels and demonstrates significant efficacy in alleviating Mycobacterium butyricum-induced foot edema in rat models of adjuvanted joint inflammation, with effective dosing in the range of 3-12 mg/kg. This compound is valuable for studies related to inflammation and joint diseases. -
Anti-inflammatory Agent
Rimexolone is a glucocorticoid steroid that functions primarily as an anti-inflammatory agent. It exhibits potent anti-inflammatory properties and is employed in the management of ocular inflammation. Its formulation as a 1% ophthalmic suspension makes it suitable for targeted treatment in various inflammatory conditions affecting the eye. -
Anti-Inflammatory agent
Fluocortin butyl ester is a topical corticosteroid with anti-inflammatory properties, demonstrating minimal systemic corticosteroid activity upon application. It has shown efficacy and good tolerance in managing symptoms of perennial rhinitis, making it a valuable reagent for research focused on inflammatory responses and related conditions. -
Anti-inflammatory Agent
Prednisolone metazoate sodium is an anti-inflammatory agent primarily used in the study of inflammatory bowel disease, ulcerative colitis, and gastrointestinal disorders. This compound exerts its biological activity by modulating the immune response and reducing inflammation, making it a valuable tool in research focused on inflammatory conditions of the gastrointestinal tract. -
RIG-I Inhibitor
RIG012 is a potent inhibitor of RIG-I with an IC50 of 0.71 μM, as determined by the NADH-coupled ATPase assay. It effectively suppresses the expression of interferon beta (IFN-β) and the interferon-stimulated gene hRsad2. RIG012 is valuable for research applications focusing on the modulation of innate immune responses and the study of viral infections. -
IRF5 Inhibitor
YE6144 is a selective interferon regulatory factor 5 (IRF5) inhibitor. It exhibits significant biological activity by suppressing disease progression and is particularly effective for maintaining remission in murine models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the mechanisms of SLE and the role of IRF5 in autoimmune diseases. -
IFN-γ Antagonist
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) functions as an antagonist of interferon-γ (IFN-γ). This compound effectively inhibits IFN-γ-induced HLR/DR antigen expression in cellular models. Its application is particularly relevant in the investigation of diseases characterized by dysregulation of immune responses. -
Antiviral Agent
2'-Deoxy-2'-fluorouridine is a nucleoside analog targeting viral replication. It effectively inhibits the replication of wild-type viruses by binding to viral RNA, while also demonstrating capacity to incorporate into DNA and RNA in vivo models. Furthermore, this compound can be utilized as a precursor in the development of respiratory syncytial virus (RSV) polymerase inhibitors. Its unique mechanism makes 2'-Deoxy-2'-fluorouridine a valuable compound for antiviral research applications. -
STING Agonist
diABZI-V/C-DBCO is a potent STING agonist with an EC50 of 1.47 nM. It activates the STING pathway to promote the production of type I interferons, particularly IFN-β, enhancing immune responses. This compound acts as a substrate for cathepsin B, leading to the release of active diABZI-amine through cathepsin B-mediated cleavage. In preclinical studies using an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO has been shown to elevate serum levels of IFN-β and increase the frequency of granzyme B+ CD8+ T cells, making it valuable for research in triple-negative breast cancer. -
STING Agonist
SNX281 is a selective STING agonist that functions by inducing homodimerization at the STING binding site, leading to a conformational shift that activates STING and initiates downstream signaling pathways. This compound effectively stimulates the production of type I interferons, including IFN-β, as well as TNF-α and IL-6, resulting in enhanced T cell responses and prolonged immune memory. SNX281 demonstrates anti-tumor activity and is valuable for research applications in colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer. -
Mi-2β-targeted Inhibitor
Z36-MP5 is a targeted inhibitor of Mi-2β, exhibiting an IC50 value of 0.082 μM. This compound effectively reduces Mi-2β ATPase activity, leading to the reactivation of interferon-stimulated gene (ISG) transcription. Additionally, Z36-MP5 is known to enhance T-cell-mediated cytotoxicity, making it a valuable tool for research in immunology and potential therapeutic applications in cancer and viral infections. -
MHC Class II Restriction Antigen
InsB (9-23) is an MHC class II-restricted peptide derived from the insulin B-chain, encompassing amino acid residues 9-23. This peptide is a critical antigen for HLA-DQ8, facilitating T cell recognition and activation, leading to the release of IFN-γ and various cytokines. InsB (9-23) has been shown to activate CD4 T cells associated with the pathogenesis of type 1 diabetes and autoimmune diabetes. It serves as an essential tool for research investigating the immunological mechanisms underlying these diseases. -
Adjuvant
CP-20961 is a synthetic non-immunogenic adjuvant with the primary mechanism of inducing interferon production. This compound has been shown to effectively enhance immune responses and modulate inflammation, making it relevant for studying autoimmune conditions such as arthritis. Its application as an adjuvant in therapeutic and vaccine research holds promise for advancing understanding of immune modulation and disease management. -
SLCl5A4 Inhibitor
IFNα-IN-1 is an SLC5A4 inhibitor that specifically targets and inhibits the production of interferon-alpha (IFN-α). Its primary biological activity is to modulate the inflammatory response by reducing IFN-α levels. This reagent is suitable for research applications focused on studying inflammation and related disease mechanisms. -
VISTA Inhibitor
VISTA-IN-3 is a potent small molecule inhibitor of the VISTA pathway, exhibiting a KD value of 0.49 μM. It effectively induces the release of IFN-γ cytokines, thereby enhancing immune responses. Additionally, VISTA-IN-3 demonstrates synergistic effects when combined with PD-L1 antibodies, making it a valuable tool for cancer immunotherapy research. -
C Class CpG ODN
ODN D-SL03 is a C class CpG oligonucleotide that primarily targets immune cells to induce the production of high levels of interferon-alpha (IFN-α) in peripheral blood mononuclear cells (PBMCs). It effectively activates human B cells, natural killer (NK) cells, and mononuclear cells while enhancing the expression of costimulatory molecules CD80, CD86, and HLA-DR on various PBMC subsets. Additionally, ODN D-SL03 exhibits tumor-inhibiting properties, making it valuable for research in immunotherapy and cancer treatment. Sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'. -
CpG-A ODN
ODN 6016 is a CpG-A oligonucleotide that acts as a potent immunostimulatory agent through the induction of interferon alpha (IFN-α) production. This compound is valuable for investigating immune disorders, particularly those related to immunodeficiency mechanisms associated with HIV-1. The specific sequence of ODN 6016 is T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G, enabling targeted research applications in the field of immunology. -
IRF4
Frenlosirsen sodium is an antisense oligonucleotide that specifically targets IRF4, a critical regulator in immune responses. This compound has demonstrated potential in the study of relapsed or refractory multiple myeloma (RRMM), facilitating research into therapeutic interventions for this challenging malignancy. Its mechanisms may provide insight into the modulation of immune pathways associated with multiple myeloma progression and treatment resistance. -
IRF4
Frenlosirsen is an antisense oligonucleotide that specifically targets interferon regulatory factor 4 (IRF4). It is utilized in research focused on relapsed or refractory multiple myeloma (RRMM), enabling the examination of therapeutic strategies aimed at modulating this transcription factor. This reagent serves as a valuable tool for understanding the role of IRF4 in tumorigenesis and resistance mechanisms in hematological malignancies. -
IFN alpha-IFNAR Inhibitor
IFN alpha-IFNAR-IN-1 is a small-molecule inhibitor that specifically targets the interaction between interferon-alpha (IFN-α) and its receptor, IFNAR. This compound effectively inhibits IFN-α responses induced by modified Vaccinia virus Ankara (MVA) in murine bone marrow-derived plasmacytoid dendritic cell (pDC) cultures, exhibiting an IC50 of 2-8 μM. It serves as a valuable tool for studying the immune response modulation in various infectious and inflammatory conditions. -
Cyclic Di-nucleotide
2'2'-cGAMP is a synthetic cyclic dinucleotide (CDN) that targets the STING (Stimulator of Interferon Genes) pathway, playing a crucial role in the immune response. It effectively induces the production of interferon-beta (IFN-β), a key cytokine involved in antiviral defense. While 2'2'-cGAMP exhibits a weaker affinity for STING compared to 2'3'-cGAMP, it demonstrates a stronger interaction than other CDNs, making it valuable for research in immunology and therapeutic applications related to immune modulation. -
IFN-RI Fusion Protein
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein that functions by binding to interferon receptors, thereby extending their serum half-life. This enhancement can facilitate prolonged biological activity and efficacy in therapeutic applications. Bifarcept is primarily utilized in research exploring the immune response and potential treatments for various diseases mediated by interferon signaling. -
IFNβ inhibitor
StA-IFN-1 is a selective inhibitor of type I interferon (IFN), specifically targeting the activation of IFNβ with an IC50 of 4.1 μM. This compound is utilized in research exploring the roles of IFNβ in immune responses and associated pathologies. Its inhibitory properties make it a valuable reagent for studying the modulation of inflammatory processes and therapeutic strategies in various disease models. -
IRF5 Inhibitor
YE6144 free base is a selective inhibitor of interferon regulatory factor 5 (IRF5). It effectively suppresses disease progression and is particularly beneficial for maintaining remission in preclinical models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the role of IRF5 in autoimmune disorders and potential therapeutic strategies for SLE. -
IRF3 Inhibitor
Sim-9 is a covalent allosteric inhibitor targeting interferon regulatory factor 3 (IRF3). By binding covalently to the Cys222 residue, Sim-9 induces a conformational change that inhibits interactions between IRF3 and key signaling partners such as TRIF, MAVS, and STING, ultimately blocking homodimerization and the type I interferon response. This compound demonstrates significant anti-inflammatory and organ-protective effects in mouse models of sepsis and acute pancreatitis, making it a valuable tool for research focused on inflammatory diseases. -
NK Cell Activator
Antitumor agent-210 is an NK cell activator known for enhancing the activation and degranulation of natural killer (NK) cells. It exerts a modest proliferative effect on NK92 cells, significantly increasing their cytotoxicity against tumor cells. This compound promotes the release of key cytokines, including granzyme B, perforin, and IFN-γ, and has demonstrated efficacy in reducing lung metastatic lesions in murine models. Antitumor agent-210 is a valuable reagent for researching melanoma lung metastasis and other cancer-related immunological studies. -
IFNAR Inducer
CP-28888 is an interferon alpha/beta receptor (IFNAR) inducer that enhances the immune response by promoting the production of type I interferons. It exhibits greater potency in murine models, making it a valuable tool for studying immune modulation and antiviral responses in preclinical research. Despite its limited efficacy in human trials and lack of antirhinovirus activity, CP-28888 remains a relevant compound in the investigation of therapeutic approaches targeting interferon pathways. -
IKZF2 degrader
NVP-DKY709 is an orally active molecular glue degrader targeting IKZF2. This compound demonstrates a Dmax of 53% and a DC50 of 4 nM, indicating potent degradation efficacy. Additionally, NVP-DKY709 can also degrade IKZF4 and SALL4 with DC50 values of 13 nM and 2 nM, respectively. Its mechanism involves binding to CRBN, altering its conformation to facilitate the recruitment and degradation of IKZF2, thereby exerting significant anti-tumor activity. This functionality positions NVP-DKY709 as a valuable tool in cancer research and therapeutic development targeting IKZF protein family members. -
PROTAC IKZF1/3 Degrader
Cemsidomide is a PROTAC degrader targeting IKZF1 and IKZF3, utilizing the ubiquitin ligase pathway. It exhibits potent biological activity with a GI50 of 0.05 nM against NCIH929.1 cells. This compound is primarily employed in the exploration of multiple myeloma (MM) research, facilitating the study of targeted protein degradation in cancer therapeutics. -
IKZF2 Molecular Glue Degrader
PLX-4545 is an orally active and selective molecular glue degrader that targets IKZF2 (zinc finger transcription factor Helios) via cereblon. This compound reprograms immunosuppressive regulatory T cells into pro-inflammatory effector T cells, thereby enhancing anti-tumor immune responses. PLX-4545 is intended for research applications related to solid tumors and the modulation of T cell functionality. -
IKZF2 Molecular Glue Degrader
(S,S)-PLX-4545 is a cereblon-based molecular glue degrader targeting IKZF2, a zinc finger transcription factor involved in immune regulation. This compound effectively promotes the degradation of IKZF2, making it a valuable tool for investigating IKZF2-related diseases, including various proliferative disorders and cancers. Researchers can leverage (S,S)-PLX-4545 to explore therapeutic strategies targeting IKZF2 functionality in different biological contexts. -
Enantiomer Of PLX-4545
(1S,2S,3R)-PLX-4545 is the (1S,2S,3R) enantiomer of PLX-4545, functioning as a selective cereblon-based molecular glue degrader that targets IKZF2 (zinc finger transcription factor Helios). This compound effectively reprograms immunosuppressive regulatory T cells into pro-inflammatory effector T cells, enhancing anti-tumor immune responses. Its applications extend to immunology and cancer research, providing insights into T cell modulation and potential therapeutic strategies for cancer immunotherapy. -
IKZF2 Selective and orally Inhibitor
PVTX-405 is a selective, orally bioavailable inhibitor targeting IKZF2, designed as a molecular glue degrader. With a DC50 of 0.7 nM and a Dmax of 91%, it enhances degradation efficiency while minimizing off-target effects, exhibiting an IC50 of 48 µM for hERG inhibition. PVTX-405 demonstrates significant antitumor activity by inhibiting the growth of MC38 tumors and shows improved efficacy when combined with immune checkpoint therapies, such as anti-PD1 or anti-LAG3, in mouse models. -
IKAROS Protein Degrader
MGD-4 is an orally bioavailable IKAROS protein degrader that operates via Cereblon (CRBN) dependence, demonstrating effective degradation of IKZF1 (DC50=67.2 nM), IKZF2 (DC50=918.2 nM), and IKZF3 (DC50=95.8 nM). It exhibits significant anti-proliferative activity against multiple myeloma, making it a valuable tool for research into therapies targeting hematological malignancies. This compound is ideal for studies investigating the role of IKAROS family proteins in cancer biology and the development of protein degradation strategies. -
USP3 ZnF-UBD Ligand
USP3 ZnF-UBD Ligand-1 is a small molecule that specifically targets the zinc finger ubiquitin-binding domain (ZnF-UBD) of USP3, exhibiting a binding affinity characterized by a KD of 14 μM. This ligand can be utilized in studies investigating the role of USP3 in ubiquitin signaling pathways and its implications in various diseases. Its ability to selectively bind to USP3 enables researchers to explore potential therapeutic strategies targeting this deubiquitinating enzyme. -
Molecular Glue IKZF2-Degrader
IKZF2-degrader 3 is a molecular glue that selectively targets and degrades the IKZF2 protein, exhibiting a DC50 of 2.0 nM. It enhances the understanding of IKZF2's role in various biological processes and is useful for studying its implications in hematological malignancies. This reagent is valuable for research focused on targeted protein degradation and its therapeutic potential in cancer treatment.
